miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator-Reference-Cited by-同舟云学术

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Published:2015-04-23 Issue:17 Volume:125 Page:2669-2677
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Husby Simon¹,Ralfkiaer Ulrik¹²,Garde Christian³⁴,Zandi Roza¹,Ek Sara⁵,Kolstad Arne⁶,Jerkeman Mats⁷,Laurell Anna⁸,Räty Riikka⁹,Pedersen Lone B.¹,Pedersen Anja¹,Ehinger Mats¹⁰,Sundström Christer¹¹,Karjalainen-Lindsberg Marja-Liisa¹²,Delabie Jan¹³,Clasen-Linde Erik²,Brown Peter¹,Cowland Jack B.¹,Workman Christopher T.³⁴,Geisler Christian H.¹,Grønbæk Kirsten¹

Affiliation:

1. Department of Hematology and

2. Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;

3. Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark;

4. Center for non-coding RNA in Technology and Health, Department of Health Sciences, University of Copenhagen, Copenhagen, Denmark;

5. Department of Immunotechnology, CREATE Health, Lund University, Lund, Sweden;

6. Departments of Oncology and Pathology, Rikshospitalet, Oslo, Norway;

7. Department of Oncology, Skåne University Hospital, Lund, Sweden;

8. Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;

9. Departments of Hematology and Oncology, Helsinki University Central Hospital, Helsinki, Finland;

10. Department of Pathology, Skåne University Hospital, Lund, Sweden;

11. Department of Immunology, Genetics, and Pathology, Uppsala University Hospital, Uppsala, Sweden;

12. Department of Pathology, Laboratory Diagnostics, Helsinki University Central Hospital, Helsinki, Finland; and

13. Department of Pathology, Division of Cancer Medicine and Surgery, Oslo University Hospital, Oslo, Norway

Abstract

Key Points miR-18b overexpression identified patients with poor prognosis in 2 large prospective homogenously treated MCL cohorts. miR-18b overexpression adds prognostic information to the MIPI-B prognosticator.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/17/2669/1384833/2669.pdf

Reference43 articles.

1. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization.;Vaandrager;Blood,1996

2. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.;Geisler;Blood,2008

3. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.;Damon;J Clin Oncol,2009

4. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.;van ’t Veer;Br J Haematol,2009

5. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.;Geisler;Br J Haematol,2012

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Noncoding RNAs in B cell non-Hodgkins lymphoma;Gene;2024-07

2. Recent advances in genomics and therapeutics in mantle cell lymphoma;Cancer Treatment Reviews;2024-01

3. miR‐17‐92 cluster‐BTG2 axis regulates B‐cell receptor signaling in mantle cell lymphoma;Cancer Science;2023-12-05

4. Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score;Leukemia & Lymphoma;2023-06-01

5. Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?;Journal of Personalized Medicine;2022-07-13